Document is current
Any future updates will be listed below
-
Authors
,
Arabi, Yaseen M.
Alothman, Adel
Balkhy, Hanan H.
Al-Dawood, Abdulaziz
AlJohani, Sameera
Al Harbi, Shmeylan
Kojan, Suleiman
Al Jeraisy, Majed
Deeb, Ahmad M.
Assiri, Abdullah M.
Al-Hameed, Fahad
AlSaedi, Asim
Mandourah, Yasser
Almekhlafi, Ghaleb A.
Sherbeeni, Nisreen Murad
Elzein, Fatehi Elnour
Memon, Javed
Taha, Yusri
Almotairi, Abdullah
Maghrabi, Khalid A.
Qushmaq, Ismael
Al Bshabshe, Ali
Kharaba, Ayman
Shalhoub, Sarah
Jose, Jesna
Fowler, Robert A.
Hayden, Frederick G.
Hussein, Mohamed A.
-
Funding
Funding for this research was provided by:
king Abdullah International Medical Research Center (RC15/142)
- License Information
-
More Information
Article History
Received: 8 May 2017
Accepted: 20 December 2017
First Online: 30 January 2018
Ethics approval and consent to participate
: The MIRACLE study is approved by the Scientific Committee and the Institutional Review Board at King Abdulaziz Medical City (RC15/142) and registered at the Saudi Food and Drug Authority (SFDA). The approval of the Ethics Committees and the SFDA will be secured from each participated sites before starting patient recruitment. Patients who meet the eligibility criteria or substitute decision-makers (for patients lacking decision-making capacity) of eligible patients will be approached to obtain informed consent for enrollment.
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
